Takeda to present oncology portfolio and pipeline data at the 2023 asco annual meeting and eha congress
Cambridge, mass. & osaka, japan--(business wire)--takeda (tse: 4502/nyse:tak) today announced that it will present data from its expanding oncology pipeline and established product portfolio at the 59th annual meeting of the american society of clinical oncology (asco) being held june 2-6, 2023, in chicago, ill. and the 31st congress of the european hematology association (eha), june 8-11, 2023, in frankfurt, germany. the company’s presence at asco 2023 will underscore takeda’s growing solid tumor portfolio, with research focused on improving treatment for metastatic colorectal cancer (crc), as well as rare forms of oncogene-driven non-small cell lung cancer (nsclc). within its hematology portfolio, takeda will present data in oral sessions at both asco and eha on a head-to-head phase 3 study comparing targeted treatments in newly diagnosed patients with philadelphia-positive acute lymphoblastic leukemia (ph+ all). “over the past year, we have made significant advancements with our pipeline – both in progress with our innate immunity enhancers and in further diversifying our pipeline – aiming to ultimately deliver transformative medicines to patients who need them most,” said awny farajallah, m.d., head, global medical affairs, oncology at takeda. “with our aspiration to cure cancer in mind, we are excited to share data from our newly expanded solid tumor portfolio featuring results in colorectal cancer, as well as research from our established hematological portfolio where we continue to explore the potential for a new standard of care treatment in acute lymphoblastic leukemia.” a full list of company-sponsored abstracts are available for asco (here) and eha (here). takeda’s commitment to oncology at takeda oncology, we are united by our aspiration to cure cancer and motivated every day to work harder for patients with limited or ineffective treatment options. our agile structure and deep in-house expertise are complemented by a network of partnerships that optimize our ability to research, develop and deliver transformative medicines to people living with cancer. building on decades of leadership in oncology and a portfolio of approved medicines for hematologic cancers and solid tumors, we are advancing a cutting-edge pipeline focused on the power of innate immunity. with inspiration from patients and innovation from everywhere, our goal is to introduce new classes of immunotherapies that can lead to deep, durable responses so that more patients can benefit from – and have access to – innovative medicines. for more information, visit www.takedaoncology.com. about takeda takeda is focused on creating better health for people and a brighter future for the world. we aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. as a leading values-based, r&d-driven biopharmaceutical company headquartered in japan, we are guided by our commitment to patients, our people and the planet. our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. for more information, visit www.takeda.com. important notice for the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by takeda pharmaceutical company limited (“takeda”) regarding this release. this press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. no shares or other securities are being offered to the public by means of this press release. no offering of securities shall be made in the united states except pursuant to registration under the u.s. securities act of 1933, as amended, or an exemption therefrom. this press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). any failure to comply with these restrictions may constitute a violation of applicable securities laws. the companies in which takeda directly and indirectly owns investments are separate entities. in this press release, “takeda” is sometimes used for convenience where references are made to takeda and its subsidiaries in general. likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. these expressions are also used where no useful purpose is served by identifying the particular company or companies. forward-looking statements this press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for takeda. without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. these forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding takeda’s global business, including general economic conditions in japan and the united states; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on takeda and its customers and suppliers, including foreign governments in countries in which takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to takeda’s operations and the timing of any such divestment(s); and other factors identified in takeda’s most recent annual report on form 20-f and takeda’s other reports filed with the u.s. securities and exchange commission, available on takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. past performance is not an indicator of future results and the results or statements of takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of takeda’s future results. medical information this press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
